Analysts downgraded ADMA Biologics to a Hold rating on September 2, 2026. The move follows a deceleration in growth and a reduction in revenue guidance for fiscal year 2026.
BIVIGAM revenue experienced a significant year-over-year decline. This slump offset robust growth from the company’s core product, ASCENIV. ADMA Biologics reported a flat topline for the first half of the year.
The analysis questioned the company's aggressive revenue targets for the second half of 2026. While valuation multiples appear low, the stock's attractiveness depends on challenging growth and margin assumptions. This downgrade follows increased scrutiny after the company’s Q2 earnings report in August.